Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cantor Fitzgerald
Daiichi Sankyo
Chinese Patent Office
US Army
Johnson and Johnson
Colorcon
McKinsey
AstraZeneca

Generated: December 9, 2018

DrugPatentWatch Database Preview

Profile for Japan Patent: H11152299

« Back to Dashboard

US Patent Family Members and Approved Drugs for Japan Patent: H11152299

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
➤ Try a Free Trial Mar 16, 2019 Astrazeneca Ab SYMLIN pramlintide acetate
US Patent Number US Expiration Date US Applicant US Tradename Generic Name

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Baxter
Chinese Patent Office
Federal Trade Commission
Citi
US Department of Justice
McKinsey
UBS
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.